Join the Clostridial Infection group to help and get support from people like you.
Clostridial Infection News
Related terms: Clostridium difficile-Associated Diarrhea, CDAD, CDI, Clostridium difficile Infection, Clostridium Infection, C. difficile, C. diff
Reduced Vancomycin Susceptibility Tied to Poorer C. Diff Outcomes
TUESDAY, April 30, 2024 – Reduced vancomycin susceptibility is impacting clinical responses among adults with Clostridioides difficile (C. difficile) infection, according to a study recently...
Vancomycin May Be Losing Strength Against Common Deadly Infection
FRIDAY, April 26, 2024 – Clostridioides difficile (C. difficile) is a leading cause of illness and death, especially for frail and hospitalized Americans. Now, a new study suggests that the leading...
AGA Recommends Fecal Microbiota Transplant for Recurrent C. Difficile
MONDAY, Feb. 26, 2024 – Fecal microbiota transplant is recommended on completion of standard-of-care antibiotics to prevent recurrence for adults with recurrent Clostridioides difficile (C....
Doxycycline Tied to Lower Risk for C. Difficile in Pneumonia Patients
THURSDAY, Nov. 30, 2023 – For patients with community-acquired pneumonia (CAP), doxycycline is associated with a reduced risk for Clostridioides difficile infection (CDI), according to a study...
Guidance Provided for Fecal Microbiota Transplantation in Children
MONDAY, Nov. 20, 2023 – For pediatric patients, fecal microbiota transplantation (FMT) is recommended for moderate-to-severe or recurrent Clostridioides difficile infection (CDI), according to a...
Simple Antibiotic Switch for Pneumonia Patients Could Prevent Hospital Infection
THURSDAY, Nov. 2, 2023 – A new study on Clostridioides difficile infections finds that choosing an alternative antibiotic for high-risk patients with pneumonia can reduce infection risk. C. diff...
Patient-to-Patient Transmission Not to Blame for Most C. Difficile Infections in Hospitals
WEDNESDAY, Sept. 20, 2023 – A deadly infection associated with hospitalization may not be the fault of the hospital, but may instead stem from the patients themselves, a new study suggests....
How NSAIDs Can Make a C. Difficile Infection Worse
FRIDAY, July 21, 2023 – Aspirin, naproxen and other common pain medications known as NSAIDs worsen gastrointestinal infections caused by a bacterium known as Clostridioides difficile (C. diff), new...
Allowing Bedside Nurses to Order C. Difficile Testing Cuts Time to Results
FRIDAY, May 26, 2023 – Allowing bedside nurses to independently order stool testing for Clostridioides difficile (C. difficile) significantly decreases the amount of time to receive test results...
Fecal Microbiota Transplantation Aids Resolution of Recurrent C. Difficile
TUESDAY, May 16, 2023 – For immunocompetent adults with recurrent Clostridioides difficile infection (rCDI), fecal microbiota transplantation (FMT) yields a significant increase in resolution...
FDA Approves Vowst (fecal microbiota spores, live-brpk) for Prevention of Recurrence of C. difficile Infection in Adults Following Antibacterial Treatment for Recurrent CDI
CAMBRIDGE, Mass. & HOBOKEN, N.J.--(BUSINESS WIRE)--Apr. 26, 2023-- Seres Therapeutics, Inc. (Nasdaq: MCRB) and Nestlé Health Science today announced the U.S. Food and Drug Administration (FDA) ...
FDA Approves Rebyota (fecal microbiota, live-jslm) Microbiota-Based Live Biotherapeutic for the Prevention of Recurrence of Clostridioides Difficile Infection
Ferring’s novel first-in-class Rebyota is indicated for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older, following antibiotic t...
FDA Approves Merck’s Dificid (fidaxomicin) to Treat Clostridioides difficile in Children Aged Six Months and Older
KENILWORTH, N.J.--(BUSINESS WIRE)-- Monday, January 27, 2020 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has...
CutisPharma Announces FDA Approval of Firvanq (vancomycin) for Treatment of Clostridium Difficile Associated Diarrhea and Staphylococcus Aureus Colitis
WILMINGTON, Mass. (Jan. 29, 2018) – CutisPharma announced today that the US Food and Drug Administration (FDA) has approved Firvanq (vancomycin hydrochloride) for oral solution, for the treatment of C...
FDA Approves Merck’s Zinplava (bezlotoxumab) to Reduce Recurrence of Clostridium difficile Infection
KENILWORTH, N.J.--(BUSINESS WIRE) October 21, 2016 --Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved...
Ask a question
To post your own question to this support group, sign in or create an account.